LAG3 and cancer: Meanwhile phase 2, NCT03044613 also evaluated the utilization of neoadjuvant nivolumab (arm A) ± relatlimab (anti-LAG-3) (ARM B) before chemoradiotherapy in resectable stage 2/3 EC or GEJ cancers, before chemoradiotherapy in resectable stage 2/3 esophageal or gastroesophageal junction (E/GEJ) cancers, with the latter regime presenting toxicity, and the former meeting primary safety points, while it has been demonstrated that patients with higher levels of LAG-3 and PD-L1 had a greater response [65].